Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by DCF Advisers LLC

Key Points

• DCF Advisers LLC reduced its stake in Eli Lilly and Company by 10.7%, owning a total of 6,250 shares after selling 750 shares in the first quarter.
• The company reported $3.34 earnings per share for the quarter, missing consensus estimates, despite significant year-over-year revenue growth of 45.2%.
• Eli Lilly recently announced a quarterly dividend of $1.50, resulting in an annualized payout of $6.00 with a yield of 0.8%.

DCF Advisers LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,250 shares of the company's stock after selling 750 shares during the quarter. Eli Lilly and Company makes up about 2.5% of DCF Advisers LLC's investment portfolio, making the stock its 8th biggest position. DCF Advisers LLC's holdings in Eli Lilly and Company were worth $5,162,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Capital International Investors increased its position in shares of Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock worth $6,740,272,000 after purchasing an additional 1,645,222 shares in the last quarter. Capital Research Global Investors increased its position in shares of Eli Lilly and Company by 16.1% during the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after purchasing an additional 1,493,673 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Eli Lilly and Company by 14.6% during the fourth quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock worth $7,294,025,000 after purchasing an additional 1,204,337 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $19.78 during trading on Wednesday, reaching $746.17. The company's stock had a trading volume of 4,705,982 shares, compared to its average volume of 3,804,386. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market cap of $707.17 billion, a price-to-earnings ratio of 60.71, a P/E/G ratio of 1.09 and a beta of 0.44. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The business's fifty day moving average price is $777.42 and its 200-day moving average price is $800.57.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim increased their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.